McKesson Corporation $MCK Stock Holdings Increased by Lazari Capital Management Inc.

Lazari Capital Management Inc. increased its holdings in McKesson Corporation (NYSE:MCK) by 165.0% in the third quarter, HoldingsChannel reports. The firm owned 1,468 shares of the company’s stock after purchasing an additional 914 shares during the period. Lazari Capital Management Inc.’s holdings in McKesson were worth $1,253,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in MCK. BlackRock Inc. bought a new stake in shares of McKesson during the 2nd quarter worth $8,156,743,000. Bank of America Corp DE raised its stake in McKesson by 2.4% during the 1st quarter. Bank of America Corp DE now owns 1,538,726 shares of the company’s stock valued at $1,331,552,000 after purchasing an additional 35,916 shares during the last quarter. Swedbank AB boosted its holdings in McKesson by 13.5% in the 1st quarter. Swedbank AB now owns 1,005,610 shares of the company’s stock valued at $870,215,000 after purchasing an additional 119,327 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in McKesson by 3.3% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 922,573 shares of the company’s stock valued at $697,096,000 after purchasing an additional 29,747 shares during the period. Finally, Legal & General Group Plc acquired a new stake in McKesson in the 2nd quarter worth $656,566,000. Institutional investors own 85.07% of the company’s stock.

Key Stories Impacting McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Analyst targets continue to rise. UBS raised its price target to $1,200, while Leerink increased its target from $1,030 to $1,070. These revisions suggest analysts see additional upside for McKesson’s pharmaceutical distribution and healthcare-services businesses. UBS raises McKesson price target Leerink raises McKesson price target
• Positive Sentiment: Strong operating performance supports investor sentiment. The company’s latest quarterly EPS beat consensus by $0.37, and revenue exceeded estimates by approximately $1.5 billion. Analysts forecast about $44.71 in EPS for the current fiscal year.
• Neutral Sentiment: Mizuho raised its target but maintained a Neutral rating. Mizuho lifted its price objective from $905 to $1,020, essentially aligning it with McKesson’s current valuation. The upgrade in target is constructive, but the Neutral rating indicates limited near-term upside from Mizuho’s perspective. Mizuho adjusts McKesson price target
• Negative Sentiment: An executive sold shares. EVP Francisco Fraga sold 800 shares worth approximately $796,640, reducing his direct holdings by 12.86%. However, the transaction was made under a pre-arranged Rule 10b5-1 trading plan, making it a relatively weak negative signal.

Insiders Place Their Bets

In other news, EVP Francisco Fraga sold 800 shares of the firm’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $995.80, for a total transaction of $796,640.00. Following the sale, the executive vice president owned 5,423 shares of the company’s stock, valued at $5,400,223.40. This trade represents a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bradley Lerman sold 301 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $892.33, for a total transaction of $268,591.33. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 1,212 shares of company stock worth $1,164,182 over the last ninety days. 0.06% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several brokerages recently issued reports on MCK. Royal Bank Of Canada restated a “sector perform” rating and set a $845.00 price target on shares of McKesson in a research note on Monday, September 14th. Wells Fargo & Company upped their price objective on shares of McKesson from $812.00 to $933.00 and gave the stock an “equal weight” rating in a research note on Tuesday, August 11th. Citigroup raised their target price on McKesson from $945.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, July 24th. UBS Group increased their price target on shares of McKesson from $1,080.00 to $1,200.00 and gave the company a “buy” rating in a research note on Friday. Finally, Bank of America raised their price target on shares of McKesson from $950.00 to $1,050.00 in a report on Thursday, August 6th. Fifteen investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $997.12.

McKesson Trading Up 1.0%

Shares of NYSE:MCK traded up $10.16 during midday trading on Tuesday, hitting $1,020.59. The company had a trading volume of 312,383 shares, compared to its average volume of 926,526. McKesson Corporation has a 12 month low of $723.68 and a 12 month high of $1,024.56. The stock has a market cap of $118.99 billion, a price-to-earnings ratio of 27.33, a PEG ratio of 2.00 and a beta of 0.30. The firm has a fifty day simple moving average of $900.34 and a 200 day simple moving average of $838.37.

McKesson (NYSE:MCK) last posted its earnings results on Wednesday, August 5th. The company reported $9.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.56 by $0.37. The company had revenue of $105.38 billion during the quarter, compared to analyst estimates of $103.88 billion. McKesson had a negative return on equity of 253.21% and a net margin of 1.12%. The company’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same period in the previous year, the company earned $8.26 EPS. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. Equities analysts forecast that McKesson Corporation will post 44.71 EPS for the current fiscal year.

McKesson Company Profile

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and medical products to pharmacies, hospitals, health systems, physicians and other healthcare providers. The company also provides technology, data and business solutions designed to support prescription management, pharmacy operations and patient care.

McKesson’s principal activities include pharmaceutical distribution, medical-surgical supply distribution, specialty pharmaceutical services and oncology care support.